Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
A
SER
vs
S&P 500
S&P 500
Over the past 12 months, SER has underperformed S&P 500, delivering a return of -58% compared to S&P 500's +10% growth.
Stocks Performance
SER vs S&P 500
Performance Gap
SER vs S&P 500
Performance By Year
SER vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
AgeX Therapeutics Inc
Glance View
AgeX Therapeutics is a biotechnology company focused on regenerative medicine. It works on cell-based therapies and related technologies that are meant to replace, repair, or restore damaged tissue, with an emphasis on conditions tied to aging and chronic disease. Its core idea is to use human stem cell science to build treatments that go beyond managing symptoms and instead aim to address the underlying tissue loss. The company’s products are still in the development stage, so it does not sell a broad line of approved drugs. Instead, it creates and advances therapeutic programs, scientific platforms, and intellectual property around stem cells and tissue regeneration. It may generate money through research partnerships, licensing, and future product sales if its candidates reach the market. AgeX sits in a part of biotech where the main value comes from owning specialized science and the rights to use it in future medicines. That makes it different from a typical drugmaker with established sales: its business depends on turning early-stage laboratory work into clinical programs that larger pharma companies, hospitals, or patients could eventually use.